Fresh Tumor Tissue vs. Dissociated Tumor Cells: Choosing the Right Biospecimen for Immuno-Oncology R&D

Immuno-oncology research is reshaping how cancer is understood and treated. For the past decade, researchers have been advancing a new generation of therapies with significant clinical promise by leveraging the body’s immune system to target tumors.

In this work, the quality and type of biological material matter. Two commonly used approaches, fresh tumor tissue and dissociated tumor cells (DTCs), offer distinct advantages depending on the research objective.

This article outlines the strengths and limitations of each, and how ABS Bio supports researchers with high-quality, fit-for-purpose specimens.

Fresh tumor tissue provides close ex-vivo representation of the tumor in its native state, including epithelial structures, stromal components and immune cell infiltration (TILs). This makes it especially valuable for studies focused on tumor–immune system interactions.

Advantages

• Microenvironment integrity: Maintains spatial relationships between tumor, blood vessels, stromal, and immune cells
• Tumor heterogeneity: Enables analysis across different regions of the same tumor
• Ex vivo applications: Supports tissue culture models, including 3D histoculture, and downstream cell line development

Considerations

• Limited viability window: Sample integrity can decline rapidly post-resection (usually 36-48 hours)
• Logistical complexity: Collection, handling, and transport require tight coordination
• Stromal interference: Can complicate isolation and analysis of specific immune populations

DTCs are prepared shortly after resection, creating a representative population of tumor cells suitable for controlled, high-throughput studies.

Advantages

Research Accuracy

• Fresh tissue: Best suited for studying tumor architecture, heterogeneity, and immune interactions
• DTCs: Ideal for controlled experiments, repeatability, and large-scale screening

Clinical Relevance

• Fresh tissue: Remains the gold standard for pathology and biomarker identification
• DTCs: Useful for long-term storage, longitudinal studies and assay development, though with more limited clinical context

• Characterizing immune cell activation and infiltration within the tumor microenvironment
• Identifying tumor-associated antigens
• Evaluating checkpoint marker expression and immune evasion mechanisms

• Detecting tumor-specific antigens for therapeutic targeting
• Monitoring post-treatment immune response
• Supporting biomarker discovery and assay development

The optimal material depends on the research goal:

• Tumor microenvironment studies → Fresh tumor tissue
• Drug candidates MOA and efficacy→ Fresh tumor 3D histoculture
• High-throughput screening or longitudinal studies → DTCs
• Metastasis and liquid biopsy research → DTCs

In many cases, a combined approach delivers the most comprehensive insight.

ABS Bio provides access to both fresh tumor tissue and dissociated tumor cells through a globally integrated network and rigorously controlled processes.

Our approach is designed to deliver:

• High-quality, viable specimens with tightly managed collection and processing timelines
• Operational reliability across procurement, logistics, and downstream handling
• Broad access to tumor types and matched samples through an established partner network
• Flexible formats to support both microenvironment-focused and high-throughput workflows

By aligning specimen type with study design and ensuring consistent quality at every step ABS Bio helps researchers generate more reliable, actionable data.

Both fresh tumor tissue and DTCs play essential roles in advancing immuno-oncology research. Each offers distinct strengths, and the right choice depends on the scientific question at hand.

With the right sourcing strategy and operational support, researchers can leverage both approaches to better understand tumor biology and accelerate the development of next-generation immunotherapies.

Most surgical resections yield approximately 200–500 mg of tissue, depending on tumor type and procedure.

DTCs are isolated shortly after resection using standardized processing protocols. ABS Bio can provide guidance based on study needs.

Fresh tissues are shipped in optimized media (e.g., HypoThermosol or DMEM) at controlled temperatures (4–6°C) with validated logistics protocols.